Home
Storia in 1 fonti
LifeSci Capital Remains a Buy on Ibio (IBIO)
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.Claim 55% Off Tip...
Raccontata da
markets.businessinsider.com
- ·
LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Inhibikase Therapeutics today and set a price target of $5.00.Claim 55% Off TipR...
- ·
LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)
LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Inhibrx Biosciences Inc today and set a price target of $230.00.Claim 55% Off...
- ·
Oculis Holding (OCS) Gets a Buy from LifeSci Capital
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Oculis Holding, with a price target of $65.00.Claim ...
- ·
LifeSci Capital Remains a Buy on Ibio (IBIO)
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.Claim 55% Off Tip...
- ·
LifeSci Capital Keeps Their Buy Rating on Immunome (IMNM)
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Immunome, with a price target of $40.00.Claim 55% Off Ti...
- ·
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.Claim 55% Off Ti...
- ·
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene today and set a price target of $60.00.Claim 55% Off TipRanksUnlock...